The Centers for Medicare and Medicaid Services (CMS) has recently disclosed the names of the top ten drugs that account for the largest portion of Medicare spending. The announcement was made publically on August 29, as the initial element in the new Medicare drug price negotiation system according to the provisions of the Inflation Reduction Act, passed in 2022. This act was legislated with the primary objective to manage and potentially reduce the cost associated with drugs under Part D of Medicare.
The full list of drugs covered under this announcement can be found within the original declaration by the CMS. The selected drugs belong to a diverse range of categories, encapsulating medications for several health condition areas. These categories are representative of the most significant drug-related expenditures within the Medicare system.
The Inflation Reduction Act, instated in 2022, has empowered the Medicare system with the explicit ability to negotiate drug prices directly with pharmaceutical companies for the first time. This power is particularly aimed at those drugs which create a significant burden on the Medicare system, such as the ones included in the list.
While it is still early days for this initiative, this represents a significant shift in the mechanisms by which drug prices are managed within the US healthcare system. Legal professionals, particularly those working within healthcare and pharmaceutical companies, will undoubtedly be watching developments with this closely.
For further information on the recent CMS announcement, you may refer directly to the original publication at JDSupra